Modern Possibilities of Usage Dupilumab in Children

Dupilumab is a genetically engineered immunobiological drug that has been increasingly used in recent years to treat bronchial asthma (BA), atopic dermatitis (AD) and eosinophilic esophagitis (EE) in children. The aim of the study is to analyze current literature data on the use of dupilumab in the treatment of BA, AD and EE in children. Despite the short history of dupilumab use in the pediatric population, its usage has shown promising results in the treatment of many conditions whose pathogenesis is T2 inflammation, primarily BA, AD and EE. It has demonstrated efficacy in patients with various clinical manifestations characterized by moderate to severe course or refractory to treatment, and has led to an improvement in the quality of life of patients. With the expansion of the use of dupilumab, there is more and more evidence of its usefulness in the treatment of other T-cell-mediated diseases.

Authors

Institutions

Publication Details

Journal
Педиатрическая фармакология
Published
2025-01-09
DOI
https://doi.org/10.15690/pf.v21i6.2827
Primary Topic
Eosinophilic Esophagitis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Modern Possibilities of Usage Dupilumab in Children

Irina R. Fomina, Dayana G. Bayburdyan, Anna A. Kosova, Saak G. Serobyan et al.
Педиатрическая фармакология
Eosinophilic Esophagitis
article

Modern Possibilities of Usage Dupilumab in Children

Irina R. Fomina, Dayana G. Bayburdyan, Anna A. Kosova, Saak G. Serobyan, Ziki Sh. Bukhsaev, Anastasiya V. Fayans, Aishan Е. Ibaduiiaeva, Kirill S. Gusev, Anastaiya N. Nikovaeva, Dmitriy V. Kaiinin, Eieonora Yu. Ivanova, Marina I. Korniiova
article en

Abstract

Dupilumab is a genetically engineered immunobiological drug that has been increasingly used in recent years to treat bronchial asthma (BA), atopic dermatitis (AD) and eosinophilic esophagitis (EE) in children. The aim of the study is to analyze current literature data on the use of dupilumab in the treatment of BA, AD and EE in children. Despite the short history of dupilumab use in the pediatric population, its usage has shown promising results in the treatment of many conditions whose pathogenesis is T2 inflammation, primarily BA, AD and EE. It has demonstrated efficacy in patients with various clinical manifestations characterized by moderate to severe course or refractory to treatment, and has led to an improvement in the quality of life of patients. With the expansion of the use of dupilumab, there is more and more evidence of its usefulness in the treatment of other T-cell-mediated diseases.

Педиатрическая фармакологияVol. 21(6)
Moscow State University of Medicine and Dentistry (RU), Sechenov University (RU), First Pavlov State Medical University of St. Petersburg (RU), Voronezh State Medical Academy named after N.N. Burdenko (RU), Pirogov Russian National Research Medical University (RU), North-Western State Medical University named after I.I. Mechnikov (RU), Kursk State Medical University (RU), Yaroslav-the-Wise Novgorod State University (RU)
Good health and well-being
Openalex Percentile: Top 99%
Eosinophilic Esophagitis
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Modern Possibilities of Usage Dupilumab in Children — Irina R. Fomina, Dayana G. Bayburdyan, et al. · Педиатрическая фармакология (2025) | TGRS Research Map | TGRS